|
Research at Hardy
Healthcare Associates
Philosophy
Research has
an important role at Hardy Healthcare Associates (HHA) even though
we are a small group practice. Conducting research is an extension
of our clinical work since we are always looking at new ideas and
for new ways of treating difficult disorders. For many years Dr.
Hardy has been on the forefront of the neuropsychopharmacologic
management of the developmental disabilities, especially autism.
During his tenure at Tufts University School of Medicine in the
Departments of Neurology and Psychiatry, Dr. Hardy lectured
extensively on this subject and helped to train medical students and
residents in this field.
During the
past several years HHA has been involved in three formal research
projects:
- Omega-3
Essential Fatty Acids in the Treatment of Autism.
- Secretin in
the Treatment of Autism. This was a phase three multi-center study
funded by the Repligen Corp.
-
aripiprazole (Abilify) in the Treatment of Autism. This is a phase
four open label trial sponsored by Bristol-Myers Squibb
Pharmaceuticals.
- Oralgam: A
Randomized, Placebo-Controlled Phase II Trial Evaluating Safety
and Efficacy of Oral Human Immunoglobulin in the Treatment of
Gastrointestinal Dysfunction Associated with Autistic Disorder in
Pediatric Patients from 2
to 18 Years of Age
|
|
